Core Viewpoint - Jinbo Biological's stock price surged to a new high following the release of its 2024 annual report, showcasing significant revenue and profit growth, which has attracted market attention [1][2]. Financial Performance - For the fiscal year 2024, Jinbo Biological reported a revenue of 1.443 billion yuan, representing a year-on-year increase of 84.9% [2][3]. - The net profit reached 732 million yuan, with a year-on-year growth of 144.3%, while the net profit excluding non-recurring items was 712 million yuan, up 149.2% [2][3]. - The company plans to distribute a generous dividend, proposing a 10-for-3 stock bonus and a cash dividend of 177 million yuan [2]. Historical Growth - Over the past three years, Jinbo Biological has consistently demonstrated impressive growth rates, with revenues increasing from 233 million yuan in 2021 to 780 million yuan in 2023, reflecting growth rates of 44.75%, 67.15%, and 99.96% respectively [3]. - Net profits also showed substantial growth, rising from 57.39 million yuan in 2021 to 300 million yuan in 2023, with growth rates of 79.62%, 90.24%, and 174.6% [3]. Market Performance - Jinbo Biological's stock was initially offered at 49 yuan per share during its IPO, and it reached a peak of 420 yuan per share, marking a maximum increase of 757.14% from the IPO price [4]. - The company raised 245 million yuan through its IPO, which was allocated to research and development of collagen products, brand building, and market promotion [4]. Product and Market Development - Jinbo Biological is recognized as the "first stock of restructured collagen" on the Beijing Stock Exchange, having launched the first injectable restructured human collagen product [5]. - In 2024, the company generated 1.254 billion yuan from medical device sales, a year-on-year increase of 84.37%, with a gross margin of 95.03% [5][6]. - The company has expanded its brand presence to approximately 4,000 medical institutions, focusing on the promotion of its "Wei Yi Mei" brand [6]. Research and Development - Jinbo Biological has significantly increased its R&D investment from 23.77 million yuan in 2020 to 123 million yuan in 2024, resulting in the acquisition of 20 new invention patents [6]. - The company has successfully developed various new types of restructured human collagen products, enhancing its core competitiveness in the market [6].
锦波生物年赚7.3亿毛利率92% 股价盘中创新高累涨757%